perspectives on metastatic hormone-sensitive prostate cancer | bayer
Published 1 year ago • 514 plays • Length 6:53Download video MP4
Download video MP3
Similar videos
-
3:51
metastatic hormone-sensitive prostate cancer (mhspc)
-
4:52
understanding metastatic hormone-sensitive prostate cancer (mhspc) with dr. fred saad
-
2:17
advanced prostate cancer and patient-centric treatment
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
46:40
updates on management of metastatic hormone-sensitive prostate cancer
-
1:36
fda approves bayer's nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer
-
46:40
updates on management of metastatic hormone-sensitive prostate cancer
-
3:15
life with prostate cancer
-
42:08
prostate cancer: clinical guidelines, novel therapies, and therapeutic uncertainty
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
1:06:24
metastatic hormone sensitive prostate cancer
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
1:26
dr. agarwal on potential agents for metastatic hormone-sensitive prostate cancer
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
2:12
abiraterone for metastatic, hormone sensitive, prostate cancer
-
4:40
axel merseburger, esmo 2019 - advances in metastatic hormone-sensitive prostate cancer
-
5:39
early treatment intensification for mcspc: optimising patient selection and treatment
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
3:20
radiation therapy for the local treatment of metastatic hormone-sensitive prostate cancer